New Delhi:
Biological E Ltd’s Covid-19 vaccine Corbevax has received an emergency use approval in India for children 12 and 18 years. The nod was given to Hyderabad-based pharmaceutical company by Drugs Controller General of India (DCGI) on Monday.
“With this approval, we are closer to finishing our global fight against the COVID-19 pandemic. Once fully vaccinated, children can resume their activities and educational pursuits in schools and colleges without any apprehension,” Mahima Dada, Managing Director, Biological E. Limited said.
Corbevax, India’s third homegrown Covid-19 vaccine, will be administered in two doses. Also, it is the third vaccine approved for use in children aged 12 and above including Zydus Cadila’s DNA shot ZyCoV-D and Bharat Biotech’s Covaxin.
Before this, Corbevax vaccine had received an approval from the DCGI’s Subject Expert Committee (SEC) for Emergency Use Authorization among the age group 12 to 18 years.
The price of the vaccine is expected to be Rs 145 excluding taxes, ANI quoted official sources as saying.
The approval is expected to further ramp up the ongoing vaccination drive for children between 15 and 18 years of age, and later for kids between 12 and 14 years of age.
On February 13, Biological E. Limited had sought the emergency use authorisation of Corbevax after which the expert panel of India’s central drug authority recommended granting restricted Emergency Use Authorisation (EUA) its vaccine Corbevax. The recommendation was then sent to the Drugs Controller General of India (DCGI) for final approval.
]]>
, International, ,